{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:31:37Z","timestamp":1793799097003,"version":"4.6.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117372","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:37:32Z","timestamp":1789184252000},"page":"117372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Assessing persistent antitumor immunity induced by tumor derived extracellular vesicle hydrogel vaccination without neoantigen identification"],"prefix":"10.1016","volume":"189","author":[{"given":"Xiaoya","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxiu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruining","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117372_bb0270","series-title":"Report tumor-intrinsic expression of signal regulatory protein \u03b1 contributes to the suppression of anti-tumor immune responses ll tumor-intrinsic expression of signal regulatory protein \u03b1 contributes to the suppression of anti-tumor immune responses","author":"Weng","year":"2026"},{"key":"10.1016\/j.intimp.2026.117372_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2022.07.002","article-title":"Inflammation: the incubator of the tumor microenvironment","volume":"8","author":"Denk","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.intimp.2026.117372_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101149","article-title":"Article loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti PD 1 therapy\u202f: strategies to restore immunotherapy sensitivity loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti PD 1 therapy\u202f: strategies to restore imm","author":"Lopez-lago","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.intimp.2026.117372_bb0065","series-title":"Article in press analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge TI ES TI IN ES. (November 2025)","author":"Communications","year":"2026"},{"key":"10.1016\/j.intimp.2026.117372_bb0245","article-title":"T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control","volume":"24","author":"Steele","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.117372_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117372_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37871","article-title":"Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer","volume":"7","author":"Goldkorn","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.intimp.2026.117372_bb0250","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117372_bb0075","series-title":"Article in press E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer TI IN ES ES. (June 2025)","author":"Communications","year":"2026"},{"key":"10.1016\/j.intimp.2026.117372_bb0255","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117372_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.03.196","article-title":"Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicentre international trial","volume":"32","author":"Jayaram","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117372_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-023-01023-3","article-title":"Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting","volume":"7","author":"Wang","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.intimp.2026.117372_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/cas.16251","article-title":"Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma","volume":"115","author":"Nakamura","year":"2024","journal-title":"Cancer Sci."},{"issue":"February","key":"10.1016\/j.intimp.2026.117372_bb0225","article-title":"Immunometabolites and cancer: the role of 2-hydroxyglutarate, succinate, fumarate and itaconate in tumour development and anti-tumour immunity","volume":"279","author":"Pfefer","year":"2026","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.intimp.2026.117372_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117409","article-title":"Ablation of the adhesion G protein-coupled receptor ADGRL1 activates anti-tumor immune response via cDC1-T cell hub formation","volume":"45","author":"Cheng","year":"2026","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-024-01528-7","article-title":"Targeting inflammation as cancer therapy","volume":"17","author":"Wang","year":"2024","journal-title":"Journal of Hematology and Oncology"},{"key":"10.1016\/j.intimp.2026.117372_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102852","article-title":"Estrogen signaling in early-stage breast cancer: impact on neoadjuvant chemotherapy and immunotherapy","volume":"132","author":"Corti","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2026.117372_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117372_bb0205","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.21037\/tcr-21-230","article-title":"Long non-coding RNAs regulating multiple proliferative pathways in cancer cell","volume":"10","author":"de Martino","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117372_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117372_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189606","article-title":"The underexplored complexity of pancreatic cancer: early dissemination and quiescence","volume":"1881","author":"Kumar","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.117372_bb0295","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/S1470-2045(26)00072-0","article-title":"Advancing cancer equity in seven high-income countries: an analysis of policy levers and National Cancer Control Plans","volume":"27","author":"Zosel","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.117372_bb0185","first-page":"1","article-title":"Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer","author":"Kureshi","year":"2026","journal-title":"Cancer Cell"},{"issue":"16_suppl","key":"10.1016\/j.intimp.2026.117372_bb0125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.2023.41.16_suppl.503","article-title":"Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials","volume":"41","author":"Gray","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0105","article-title":"Revolutionizing cancer treatment: the rise of personalized immunotherapies","volume":"15","author":"Fayyaz","year":"2024","journal-title":"Discover Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117372_bb0055","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117372_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117009","article-title":"FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages","volume":"45","author":"Chen","year":"2026","journal-title":"Cell Rep."},{"issue":"May","key":"10.1016\/j.intimp.2026.117372_bb0285","article-title":"Combination of APS, HMGN1, and anti-TNFR2 antibody remodels the tumor immune microenvironment to enhance antitumor immunity in colorectal cancer","volume":"69","author":"Zhao","year":"2026","journal-title":"Transl. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117372_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112978","article-title":"Genome-guided discovery of cancer therapeutic targets","volume":"42","author":"Konda","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.117372_bb0070","series-title":"Article in press complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases TI ES TI. (October 2025)","author":"Communications","year":"2026"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-01985-1","article-title":"Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-\u03baB p65 nuclear translocation","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02069-w","article-title":"Cancer, metastasis, and the epigenome","volume":"23","author":"Kiri","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.117372_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105940","article-title":"The ESMO\/SIOG Cancer in the elderly working group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer","volume":"11","author":"Baldini","year":"2026","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-024-00571-2","article-title":"Prioritization of therapeutic targets for cancers using integrative multi-omics analysis","volume":"18","author":"Jin","year":"2024","journal-title":"Hum. Genomics"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-02020-z","article-title":"Aging and cancer","volume":"23","author":"Mont\u00e9gut","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117372_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2026.111841","article-title":"Defining disease recurrence after curative treatment of esophageal cancer: a literature review","volume":"52","author":"Huizer","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.intimp.2026.117372_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2026.03.011","article-title":"A roadmap to embedding real-world evidence into health technology assessment processes for Cancer medicines: experiences from Scotland","author":"Mueller","year":"2026","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0025","doi-asserted-by":"crossref","DOI":"10.1007\/s44178-024-00077-w","article-title":"Cancer-triggered systemic disease and therapeutic targets","volume":"3","author":"Cao","year":"2024","journal-title":"Holistic integrative Oncology"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Communication and Signaling"},{"issue":"October 2025","key":"10.1016\/j.intimp.2026.117372_bb0110","article-title":"Potential induction of protective anti-tumor immune response in cancer patients by oncolytic viruses containing the GGTA1 gene","volume":"236","author":"Galili","year":"2026","journal-title":"Eur. J. Cancer"},{"issue":"April","key":"10.1016\/j.intimp.2026.117372_bb0230","article-title":"Colon cancer with a peritumoural abscess: real-world evidence on prognostic and therapeutic implications of a disregarded entity","volume":"240","author":"Rademaker","year":"2026","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-023-01398-5","article-title":"Interplay of oxidative stress, cellular communication and signaling pathways in cancer","volume":"22","author":"Iqbal","year":"2024","journal-title":"Cell Communication and Signaling"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0030","article-title":"Spatiotemporally engineered tumor-derived extracellular vesicle-based scaffold vaccine for personalized cancer immunotherapy","volume":"17","author":"Chen","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117372_bb0080","series-title":"Article in press pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells TI IN","author":"Communications","year":"2026"},{"issue":"14","key":"10.1016\/j.intimp.2026.117372_bb0040","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/0008-5472.CAN-24-3840","article-title":"A machine learning-based strategy predicts selective and synergistic drug combinations for relapsed acute myeloid Leukemia","volume":"85","author":"Chen","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.117372_bb0290","article-title":"IDR-driven LLPS of GAS2L3 scaffolds CHMP4B condensates to accelerate cytokinesis in hepatocellular carcinoma cells","volume":"xxxx","author":"Zhao","year":"2025","journal-title":"J. Adv. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117372_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.115756","article-title":"Distinct cytokines regulate gene expression and anti-tumor activity in regenerated CD8+ T cells from induced pluripotent stem cells","volume":"29","author":"Kondo","year":"2026","journal-title":"IScience"},{"issue":"2","key":"10.1016\/j.intimp.2026.117372_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2026.201230","article-title":"CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses","volume":"34","author":"Li","year":"2026","journal-title":"Molecular Therapy Oncology"},{"key":"10.1016\/j.intimp.2026.117372_bb0045","doi-asserted-by":"crossref","unstructured":"Chen, Y., Luo, X., Wang, Z., Duan, J. ao, & Xiao, P. (2026b). A comprehensive review of mucilage polysaccharides with dual immunomodulatory and anti-tumor activities: mechanisms, structure-activity relationships and application prospects in tumor immunotherapy. Pharmacol. Res., 229(May), 108256. Doi: https:\/\/doi.org\/10.1016\/j.phrs.2026.108256.","DOI":"10.1016\/j.phrs.2026.108256"},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-22235-8","article-title":"Naturally-occurring spinosyn a and its derivatives function as argininosuccinate synthase activator and tumor inhibitor","volume":"12","author":"Zou","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117372_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123123","article-title":"Nexus of NF\u03baB\/VEGF\/MMP9 signaling in diabetic retinopathy-linked dementia: management by phenolic acid-enabled nanotherapeutics","volume":"358","author":"Singh","year":"2024","journal-title":"Life Sci."},{"issue":"18","key":"10.1016\/j.intimp.2026.117372_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202301339","article-title":"Biomaterials facilitating dendritic cell-mediated cancer immunotherapy","volume":"10","author":"Dong","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117372_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114287","article-title":"The MO25 protein Pmo25 functions in contractile ring stability and Sid2 localization during cytokinesis","volume":"29","author":"Ye","year":"2026","journal-title":"IScience"},{"key":"10.1016\/j.intimp.2026.117372_bb0015","doi-asserted-by":"crossref","unstructured":"Bergen, T. van, Bosch, D., Bellann\u00e9-Chantelot, C., Mulet-Lazaro, R., Bledsoe, J. R., Chen, L., de Looper, H. W. J., Dijk, C. van, ter Borg, M., Bindels, E., Hoogenboezem, R., Roovers, O., Olofsen, P. A., Bartels, M., van Montfrans, J. M., Breed, P., Salzer, E., Holierhoek, M. G., Nelken, B., \u2026 Aalbers, A. M. (2025). Germline LCP1 mutations cause immunodeficiency with neutropenia, monocytopenia, lymphopenia and defective cytokinesis. Blood Adv., 10(3). Doi: https:\/\/doi.org\/10.1182\/bloodadvances.2025016507.","DOI":"10.1182\/bloodadvances.2025016507"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926012191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926012191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:53:38Z","timestamp":1793796818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926012191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"alternative-id":["S1567576926012191"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117372","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing persistent antitumor immunity induced by tumor derived extracellular vesicle hydrogel vaccination without neoantigen identification","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117372"}}